Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rigel Pharmaceuticals Inc. (New) (RIGL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $44,40, with a market capitalisation of $847,13M and a P/E ratio of 2,57. Over the past 52 weeks, its price has ranged from $24,95 to $52,24. This page covers its latest market performance, valuation, price trends and company information.
$847,13M | |
$45,14 | |
$310,00 | |
$6,40 | |
$45,35 | |
213,75K | |
339,99K | |
2,57 | |
$52,24 | |
$24,95 | |
-- | |
-- |
Rigel Pharmaceuticals Inc. (New) (RIGL) is trading at $45,46 in pre-market trading as of 2026-09-15 23:31:00, up 0,24% ($0,11) from the previous close of $45,35
Pre-market trading shows how investors are pricing RIGL before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Rigel Pharmaceuticals Inc. (New) (RIGL) moved from $48,67 to $44,40, representing a decline of 8,78% ($4,27).
The stock traded between $44,22 and $48,87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 207,82 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 71,3%
RIGL is currently trading at $44,40, placing it 71,3% of the way from its 52-week low of $24,95 to its 52-week high of $52,24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 174 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rigel Pharmaceuticals Inc. (New) (RIGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.